GGB Awards Return To Frankfurt In 2025

Entries Are Now Open Ahead Of 29 October Awards Ceremony In Germany

The Global Generics & Biosimilars Awards is taking place in Frankfurt this October, with the event returning to Germany in its twelfth year for an even bigger and better awards ceremony that will recognize the most outstanding achievements across the generics, biosimilars and value added medicines industries. Entries are now open and you can also book tickets to attend, both of which are free of charge.

The GGB Awards 2025 will take place on 29 October in Frankfurt (Shutterstock)

Frankfurt is the venue for the Global Generics & Biosimilars Awards 2025, with entries now open for our annual celebration of the off-patent industry’s leading accomplishments, ahead of a prizegiving ceremony that will take place on Wednesday 29 October, during CPhI Worldwide week.

Now in their twelfth year, the awards – which are free to enter and attend, with our awards ceremony taking place at the Radisson Blu Hotel, Frankfurt – celebrate the greatest achievements across the generics, biosimilars and value added medicines industries.

Entries are open until Friday 1 August 2025 and can cover any activities undertaken between 1 August 2024 and 31 July 2025. As in previous years, our categories include:

  • Company of the Year
  • Regional Companies of the Year – Americas, APAC and EMEA
  • Acquisition of the Year
  • Leader of the Year
  • Value Added Medicine Initiative of the Year
  • Business Development of the Year
  • API Supplier of the Year
  • Biosimilar Initiative of the Year
  • Regulatory Achievement of the Year
  • Corporate Social Responsibility (CSR) Initiative of the Year
  • Industry Partner of the Year
  • Campaign of the Year

Our CSR Initiative of the Year award will once again be supported by longtime associate International Health Partners.

“We can’t wait to be back in Frankfurt, in an impressive new venue, to celebrate the greatest achievements seen this year by the global generics, biosimilars and value added medicines industry,” commented Dave Wallace, executive editor of Generics Bulletin.

“With the off-patent industry playing an increasingly important role in contributing valuable treatments to healthcare systems worldwide at affordable prices, while also broadening access to essential medicines, we’re proud to be shining the spotlight on the companies and individuals that are leading these achievements.”

The Global Generics & Biosimilars Awards prides itself on its independence, with winners chosen solely on merit and acknowledged as the most deserving of recognition for their unique achievements.

All submissions are reviewed by an independent panel of expert judges, who have been selected on the basis of their industry knowledge and impartiality.

For a full list of the awards categories, submissions criteria, how to attend and other information, go here.

To enquire about sponsorship opportunities, please e-mail George.Wilkins@citeline.com

And to register interest in attending the Global Generics & Biosimilars Awards 2025, to receive the latest updates and for any further details, please e-mail Natalia.Kay@citeline.com

More from Generics

Teva Provigil ‘Pay For Delay’ Fines Should Stand, AG Says

 
• By 

Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.

Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs

 
• By 

Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.

Optum Rx Remodels Payment Model To Favor Generics – A Peace Offering For FTC?

 

Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Combating Bioequivalence Data Fraud: Indian CROs Face Mandatory Registration

 

As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.

More from Value Added Medicines

With New Data, Lipella Plots 2025 Milestones For Oral Rinse Tacrolimus

 
• By 

Reformulation specialist Lipella has an eye on numerous milestones for its proposed oral rinse liposomal formulation of tacrolimus, including the submission of a Phase IIb clinical trial investigational new drug application.

Adial Is Filling The Gap In Alcohol Use Disorder Treatment With Repurposed Drug

 

Adial Pharmaceuticals’ CEO Cary Claiborne discussed with Generics Bulletin how repurposing antinausea drug ondansetron and genetically targeting patients with specific biomarkers can address the unmet need in the current treatment of addiction.

Building A Sustainable Market: New Medicines For Europe President Sets Out Priorities

 
• By 

Recently-appointed president of Medicines for Europe Stephan Eder speaks to Generics Bulletin about the off-patent association’s priorities to secure a sustainable operating environment for the generics, biosimilars and value-added medicines sector in Europe.